Smad7 Antisense Oligonucleotide-Based Therapy in Crohn's Disease: Is it Time to Re-Evaluate?

Abundant preclinical work showed that in Crohn’s disease (CD), the defective activity of the immunosuppressive cytokine tumor necrosis factor (TGF)-β1 due to high levels of the intracellular inhibitor Smad7 contributes to amplify the tissue-damaging inflammatory response. Consistently, phase I and I...

Descripción completa

Detalles Bibliográficos
Autores principales: Monteleone, Giovanni, Stolfi, Carmine, Marafini, Irene, Atreya, Raja, Neurath, Markus F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2022
Materias:
Current Opinion
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9411088/
https://www.ncbi.nlm.nih.gov/pubmed/35841457
http://dx.doi.org/10.1007/s40291-022-00606-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9411088/
https://www.ncbi.nlm.nih.gov/pubmed/35841457
http://dx.doi.org/10.1007/s40291-022-00606-1

Ejemplares similares